SOST and chronic kidney disease: By intervention with an anti-resorptive agent, Miyaoka et al. found denosumab had reno-protective effects with the reverse of the age-related decrease of eGFR by inhibiting bone resorption and suppressing seral phosphate load in non-CKD patients [33], which indicated a possible role of manipulating sclerostin toward renal or vascular protection.